The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.

摘要: Angiotensin II receptor blockers (ARBs) are the most recent class of anti-hypertensive drug to enter clinical use for chronic heart failure (CHF). In landmark Valsartan Heart Failure Trial (Val-HeFT), valsartan reduced risk combined endpoint all-cause mortality and morbidity by 13.2% over a 2-year follow-up. Although it significantly improved pre-specified primary endpoint, did not improve mortality. administered patients receiving angiotensin-converting enzyme inhibitors (ACEI) at baseline 33% 44%, compared with placebo. Based on these findings, became first ARB be approved US Food Drug Administration treatment New York Association II-IV HF in who intolerant ACEIs. This review provides summary key Val-HeFT results their implications CHF patients.